Business Wire

SAMSUNG-ELECTRONICS

9.9.2021 10:02:12 CEST | Business Wire | Press release

Share
Samsung Receives Its First Global Carbon Footprint Certification for Logic Chips

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that four of its System LSI products received product carbon footprint label certification from the Carbon Trust, the first of Samsung’s logic chips to do so.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005409/en/

Having received the semiconductor industry’s first carbon footprint accreditation for memory chips from the Carbon Trust in 2019, Samsung has now broadened its ESG (Environmental, Social, and Governance) spectrum with this global recognition of ‘eco-friendly’ logic chips. Samsung also grabbed the industry’s first triple Carbon Trust Standard for Carbon, Water and Waste in June 2021.

The Carbon Trust is an independent and expert partner of organizations around the world that advises businesses on their opportunities in a sustainable, low carbon world. The Carbon Trust also measures and certifies the environmental footprint of organizations, supply chains and products.

Of the various certification categories of the Carbon Trust, Samsung’s System LSI products received the CO2 Measured product carbon footprint label. The label certifies the chip’s carbon footprint, which informs consumers of the impact that the product and its manufacturing process have on the environment.

Receiving the CO2 Measured label is a critical first step for carbon reduction, since it verifies the current carbon emissions of the product with globally recognized specifications (PAS 2050), which Samsung can use as a benchmark to measure future carbon reductions.

Correctly measuring the carbon footprint of a product requires extensive effort and time. It involves calculating the amount of carbon emitted from fabricating raw subsidiary materials and transporting the product, as well as the carbon emission from using electricity, water, and gas. The hundreds of fabrication processes needed to make a semiconductor chip adds to the complication.

“We’re pleased to have worked with Samsung on this step in its sustainability journey,” said Hugh Jones, managing director at the Carbon Trust Advisory. “The Carbon Trust’s Carbon Measured certification is a clear and credible indicator for consumers that the carbon footprint of these products have been independently verified, as well as a baseline for Samsung to compare against as they work towards reducing their emissions in the future.”

The four products to receive certification include a variety of Samsung’s System LSI chips, from mobile processors to image sensors. The Exynos 2100, one of the four products to receive certification, is a high-performance mobile processor built with the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node. The 0.7-micrometer (μm)-pixel image sensor ISOCELL HM2, DTV SoC (S6HD820), and TCON (S6TST21) also received certification by the Carbon Trust.

Including the four chips, Samsung has so far received certifications for fourteen of its semiconductor products from the Carbon Trust.

“We are thrilled to be globally acknowledged for our eco-friendly efforts,” said Seong-dai Jang, senior vice president and head of DS Corporate Sustainability Management Office at Samsung Electronics. “We will continue to fulfill our carbon reduction goals and expand our efforts to a wider range of eco-friendly, high-performance products to meet the global standards for a sustainable future.”

Exynos 2100

Based on 5nm EUV process technology, the Exynos 2100 is Samsung’s first 5G-integrated flagship mobile processor for premium mobile devices. The Exynos 2100 performs up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation.

ISOCELL HM2

The ISOCELL HM2 is a 0.7μm-pixel image sensor that opened up the market for ultra-high resolutions. The 108MP-sensor is around 15 percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent, while featuring faster autofocus, nine-pixel binning and 3x lossless zoom.

DTV SoC (S6HD820)

Samsung’s DTV SoC (S6HD820) is an essential component in television as picture quality evolves from 4K to 8K standard. The DTV SoC’s NPU (neural processing unit) allows AI technology to improve picture quality and audio processing.

TCON (S6TST21)

A TCON takes video data from the DTV SoC and converts it according to the demands of the DDI (Display Driver IC). The data transmission speed of the TCON is important when it comes to quickly transmitting high-resolution video data to the DDI. Samsung’s TCON (S6TST21) integrates two 8K 60-hertz (Hz) chips to minimize energy loss.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye